Overexpression of B7‑H4 promotes renal cell carcinoma progression by recruiting tumor‑associated neutrophils via upregulation of CXCL8

Li, Anqi; Zhang, Ningyue; Zhao, Zhiming; Chen, Yali; Zhang, Liang

doi:10.3892/ol.2020.11701

Cited by 7 publications

(5 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The bulk of the researchers have reported the mechanism of the mutual effect between VTCN1 and infiltrating immune cells leading to tumorigenesis. Overexpression of VTCN1 accelerates renal cell carcinoma advancement by recruitment of tumorrelated neutrophils up-regulating the CXCL8 in the report by Li et al [33] . Others included cervical cancer [34] , thymic epithelialtumor [24] , epithelial ovarian cancer [35] , metastatic colorectal cancer [28] , and non-small cell lung cancer [36] , where the connection between VTCN1 and immune cells was explained severally.…”

Section: Experimental Verificationmentioning

confidence: 90%

A Pan-Cancer Analysis Indicates the Prognostic Significance and Immunological Function of V-Set Domain Containing T-Cell Activation Inhibitor 1

Yu,

feng,

et al. 2023

IJPS

View full text Add to dashboard Cite

The immune costimulatory protein V-set domain containing T cell activation inhibitor 1 is a key molecule in the B7 family developing advanced growth in multiple cancers as a suppressive regulatory factor during T cell immunoreaction. For the purpose of confirming the importance of prognosis and ascertaining the effects on tumor immunity of V-set domain containing T cell activation inhibitor 1 gene expression across diverse cancers. The design utilized a wide range of tools involved in bioinformatics from the available public database to integrally identify the association between V-set domain containing T cell activation inhibitor 1 and prognosis, clinic pathological features, tumor mutational burden, microsatellite instability, methyl transferase, mismatch repair, immune cell permeation among different tumors, chemotherapy drug sensitivities, and try to comprehensively probe potentially carcinogenic of V-set domain containing T cell activation inhibitor 1. The results exhibited that V-set domain containing T cell activation inhibitor 1 was overexpressed in various tumor types. As an independent risk factor for the prognosis of 12 different cancer types, V-set domain containing T cell activation inhibitor 1 expression had a connection with survival status. Additionally, it is advantageous in 15 different cancer types for diagnosis. Meanwhile, in 10 and 7 cancer types, the expression of V-set domain containing T cell activation inhibitor 1 was distinctly correlated to tumor mutational burden and microsatellite instability. And the close connection of V-set domain containing T cell activation inhibitor 1 with immune cell infiltration was considered, especially T cells cluster of differentiation 8+, T cells cluster of differentiation 4+, neutrophils, myeloid dendritic cells, macrophages and B cells within most types of cancer. The implication of V-set domain containing T cell activation inhibitor 1 showed the valuable prognostic potentiality in multiple cancers, and it may function as an immunotherapy target in multiple malignant tumors according to the impact on tumorigenesis and tumor immunity.

show abstract

Section: Experimental Verificationmentioning

confidence: 90%

A Pan-Cancer Analysis Indicates the Prognostic Significance and Immunological Function of V-Set Domain Containing T-Cell Activation Inhibitor 1

Yu,

feng,

et al. 2023

IJPS

View full text Add to dashboard Cite

show abstract

“…120 Recent studies indicated the broad spectrum of patients' tumors that have been associated with aberrant B7-H4 expression across a wide variety of cancers, including colorectal, craniopharyngioma, RCC, BC, prostate cancer, pancreatic cancer, esophageal squamous cell carcinoma (ESCC), and cervical cancer. [137][138][139][140][141][142][143][144] Furthermore, serum sB7-H4 may be a valuable prognostic marker in patients in this wide spectrum of cancers. In patients with non-metastatic ccRCC, the high levels of sB7-H4 along with elevated PB neutrophil count were associated with either poor progression-free survival (PFS) or OS.…”

Section: New B7 Family Checkpoints Moleculesmentioning

confidence: 99%

Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands

Kamali,

Bautista,

Eisenhut

et al. 2023

Therapeutic Advances in Vaccines and Immunotherapy

View full text Add to dashboard Cite

Checkpoint markers and immune checkpoint inhibitors have been increasingly identified and developed as potential immunotherapeutic targets in various human cancers. Despite valuable efforts to discover novel immune checkpoints and their ligands, the precise roles of their therapeutic functions, as well as the broad identification of their counterpart receptors, remain to be addressed. In this context, it has been suggested that various putative checkpoint receptors can be induced upon activation. In the tumor microenvironment, T cells, as crucial immune response against malignant diseases as well as other immune central effector cells, such as natural killer cells, are regulated via co-stimulatory or co-inhibitory signals from immune or tumor cells. Studies have shown that exposure of T cells to tumor antigens upregulates the expression of inhibitory checkpoint receptors, leading to T-cell dysfunction or exhaustion. Although targeting immune checkpoint regulators has shown relative clinical efficacy in some tumor types, most trials in the field of cancer immunotherapies have revealed unsatisfactory results due to de novo or adaptive resistance in cancer patients. To overcome these obstacles, combinational therapies with newly discovered inhibitory molecules or combined blockage of several checkpoints provide a rationale for further research. Moreover, precise identification of their receptors counterparts at crucial checkpoints is likely to promise effective therapies. In this review, we examine the prospects for the application of newly emerging checkpoints, such as T-cell immunoglobulin and mucin domain 3, lymphocyte activation gene-3, T-cell immunoreceptor with Ig and ITIM domains (TIGIT), V-domain Ig suppressor of T-cell activation (VISTA), new B7 family proteins, and B- and T-cell lymphocyte attenuator, in association with immunotherapy of malignancies. In addition, their clinical and biological significance is discussed, including their expression in various human cancers, along with their roles in T-cell-mediated immune responses.

show abstract

“…The chemokine CXCL8 and the chemokine receptor CXCR4 are also involved in the recruitment of neutrophils in the tumor microenvironment. Inhibiting CXCL8 or blocking CXCR4 can inhibit the infiltration of TANs in TME ( 304 – 307 ). IL-6 can also attract TANs to the tumor environment and can attenuate and reverse the pro-inflammatory effects of neutrophils in the tumor microenvironment thus leading to immune-killing resistance.…”

Section: Tans-targeted Therapymentioning

confidence: 99%

Therapeutic strategies for gastric cancer targeting immune cells: Future directions

et al. 2022

View full text Add to dashboard Cite

Gastric cancer (GC) is a malignancy with a high incidence and mortality, and the emergence of immunotherapy has brought survival benefits to GC patients. Compared with traditional therapy, immunotherapy has the advantages of durable response, long-term survival benefits, and lower toxicity. Therefore, targeted immune cells are the most promising therapeutic strategy in the field of oncology. In this review, we introduce the role and significance of each immune cell in the tumor microenvironment of GC and summarize the current landscape of immunotherapy in GC, which includes immune checkpoint inhibitors, adoptive cell therapy (ACT), dendritic cell (DC) vaccines, reduction of M2 tumor-associated macrophages (M2 TAMs), N2 tumor-associated neutrophils (N2 TANs), myeloid-derived suppressor cells (MDSCs), effector regulatory T cells (eTregs), and regulatory B cells (Bregs) in the tumor microenvironment and reprogram TAMs and TANs into tumor killer cells. The most widely used immunotherapy strategies are the immune checkpoint inhibitor programmed cell death 1/programmed death-ligand 1 (PD-1/PD-L1) antibody, cytotoxic T lymphocyte–associated protein 4 (CTLA-4) antibody, and chimeric antigen receptor T (CAR-T) in ACT, and these therapeutic strategies have significant anti-tumor efficacy in solid tumors and hematological tumors. Targeting other immune cells provides a new direction for the immunotherapy of GC despite the relatively weak clinical data, which have been confirmed to restore or enhance anti-tumor immune function in preclinical studies and some treatment strategies have entered the clinical trial stage, and it is expected that more and more effective immune cell–based therapeutic methods will be developed and applied.

show abstract

Overexpression of B7‑H4 promotes renal cell carcinoma progression by recruiting tumor‑associated neutrophils via upregulation of CXCL8

Cited by 7 publications

References 48 publications

A Pan-Cancer Analysis Indicates the Prognostic Significance and Immunological Function of V-Set Domain Containing T-Cell Activation Inhibitor 1

A Pan-Cancer Analysis Indicates the Prognostic Significance and Immunological Function of V-Set Domain Containing T-Cell Activation Inhibitor 1

Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands

Therapeutic strategies for gastric cancer targeting immune cells: Future directions

Contact Info

Product

Resources

About